By Colin KellaherHumacyte has won U.S. Food and Drug Administration priority review for its application seeking approval of its Human Acellular Vessel bioengineered tissue in certain patients with vascular trauma. The Durham, N.C., clinical-stage biotechnology platform company on Friday said the application covers the product in urgent arterial repair following extremity vascular trauma when synthetic graft isn't indicated and when autologous vein use isn't feasible.

Source: Wall Street Journal February 10, 2024 01:18 UTC